Investment analysts at StockNews.com began coverage on shares of Oragenics (NYSE:OGEN – Get Free Report) in a research report issued on Sunday. The brokerage set a “sell” rating on the stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback